Top Diagnostics Startups in 2027

Altis Labs is the AI-powered computational imaging company advancing precision medicine. Trained on the world's largest cancer imaging database, our deep learning models predict outcomes to quantify treatment effect more accurately. Leading biopharmaceutical companies use our AI platform, Nota, to analyze clinical trial imaging data in a more meaningful way, allowing them to develop effective novel therapies faster. Founded in 2019, Altis is a venture-backed company headquartered in Toronto. We are actively growing our team in Canada and the US across functional areas.

Next generation Point-of-Care Coagulation Viscoelastic Diagnostic CoagCare platform for improved patient outcomes

Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts.

IonPath is a Stanford University spin-out with a vision to transform clinical pathology and tumor imaging, a $10B+ market, with the company's novel, highly multi-parametric imaging technology, Multiplexed Ion Beam Imaging (MIBI). IonPath's MIBI is a step-change improvement over the current leading tumor imaging method, immunohistochemistry (IHC). MIBI enables researchers, pathologists, and clinicians to quantitatively analyze and visually display the complex interactions among cancer tumor cells, proteins, antibodies, T-cells, and other relevant features on cells' surfaces and interiors. Understanding these biological players and their interactions should substantially improve cancer research and drug discovery, produce novel diagnostics, and transform the study of disease mechanisms such as cancer ("pathology"). IonPath will develop and commercialize services, instruments, reagents, and ultimately diagnostic tests based on MIBI technology.

Clinia is healthcare platform on a mission to transform the conventional patients and healthcare providers experience. Technology is used to make it accessible, efficient and convenient to the masses.

Welcome to HeartFlow, recipient of the 2011 EuroPCR Innovation award. Read to learn about non-invasive FFRCT (computed FFR), DISCOVER-FLOW and DeFACTO studies

The human microbiome is the next frontier of precision medicine. Just like our genes, our microbiome is unique and can help predict our health in many ways, from our disease risk to how the drugs we take effect us. Most importantly, unlike our genes, it's dynamic - so can be harnessed for better health. There's just one problem - that same dynamism makes it extremely challenging to study, and that slows progress. Microbiome researchers need more data to turn potential into reality. That's why we're creating novel tools to track, analyze, and store daily microbiome profiles of clinical trial participants, providing vastly more data than is possible with current tools, all for a fraction of the cost. This gives investigators far deeper insight into how the microbiome influences and is influenced by clinical interventions. The outcome? Microbiome-based prescriptions and solutions that are personalized to meet patient needs.

We started Teiko Bio to use immune insights to help deliver life-changing therapies to those who need them most. Today, Teiko delivers on its mission by supporting therapy development and informing clinical decision-making. By using cutting-edge mass cytometry, Teiko’s leading assay, the TokuProfile, maps characteristics of response, accelerates clinical pipeline candidates, and supports identification of novel discoveries.

Mammoth biosciences is harnessing the diversity of nature to power the next generation of crispr products. through its discovery of novel crispr systems, the company is enabling the full potential of its platform to read and write the code of life. with a distinguished team including co-founder and crispr-cas gene editing co-inventor jennifer doudna, mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.